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EBV associated hemophagocytic lymphohistiocytosis and EBV-positive T cell lymphoproliferative disease of childhood sharemany
histologic and clinical features, which sometimes makes it very difficult to render a definitive diagnosis. In this report, we present
a 16-year-old male who developed symptoms clinically consistent with EBV associated hematophagocytic lymphohistiocytosis
including fulfilling most of HLH diagnostic criteria and responding promptly to HLH targeted therapy. However, histologic and
cytogenetics features of this case are very concerning for EBV-positive T cell lymphoproliferative disease of childhood. This case
demonstrates an ambiguous boundary of these two disease entities and emphasizes the importance of comprehensive evaluation
and clinical correlation with cases suspicious of EBV driven hemophagocytic or lymphoproliferative process.
1. Introduction
Hemophagocytic lymphohistiocytosis (HLH) is clinical syn-
drome characterized by fever, splenomegaly, pancytopenia,
liver dysfunction, and coagulopathy. It is believed that there is
an uncontrolled hyperinflammatory process associated with
proliferation of activated lymphocytes and histiocytes which
secrete excessive amount of proinflammatory cytokines. His-
tologically, proliferation of lymphocytes, histiocytes, and
often hemophagocytosis are seen in bone marrow, spleen,
and lymph nodes. There are two forms of HLH: primary
HLH and secondary HLH. Primary HLH is an autosomal
recessive disease featured by defects in a set of genes including
PRF1, UNC13D, or STX11 [1]. Secondary HLH occurs after
a strong immunologic activation, such as systemic infec-
tion, immunodeficiency, or malignancy. Epstein-Barr virus
(EBV) is the most common infectious etiology for devel-
opment of secondary HLH (EBV-HLH) usually following
a primary EBV infection in adolescents. The EBV infests
T cells, leading to monoclonal/oligoclonal expansion of
T cells. Immunochemotherapy is most common treatment
and consists of corticosteroid, etoposide, and cyclosporin [2].
The prognosis is guarded with an overall mortality of ∼50%.
On the other hand, EBV infection in adolescents can rarely
evolve to a malignant T cell proliferative process known as
EBV-positive T cell lymphoproliferative disease of childhood
as described in WHO hematopoietic disorder classification
[3]. This disease is characterized by an extremely high mor-
tality rate despite aggressive management. However, it has
significant overlapping features with EBV associated HLH
including T cell immunophenotypic aberrancy and T cell
clonality, which pose a diagnostic difficulty [4].
Herein, we report a case with clinical features of EBV
associated HLHwhich was associated with a rather abundant
clonal CD8+ T cell expansion. These T cells demonstrated
aberrant antigen expression and harbored EBV. Cytogenet-
ics study demonstrated abnormal karyotype. These features
raised a concern for EBV driven neoplastic process. However,
the overall clinical course was more in line with a reactive
process.
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Figure 1: Histologic features of bonemarrow. (a) Bonemarrow biopsy demonstrated hypocellularmarrowwith prominent lymphohistiocytic
infiltrates. Black arrow in the inset pointed to a histiocyte with engulfed hematopoietic elements. (b) Immunohistochemical stain of CD68
showed increased histiocytes. (c) Bone marrow aspirate smears highlighted hemophagocytosis (black arrow) and atypical lymphoid cell (red
arrow).
2. Case Presentation
2.1. Initial Clinical Presentation. A 16-year-old previously
healthy white male initially presented with fever, sore throat,
and skin rash involving upper arms and face. A diagnosis of
infectious mononucleosis was rendered based on the clinical
symptoms and apositive EBV-VCA IgM titer at an outside
institute. He was managed by supportive measurements.
However, his symptom was worsening and subsequent lab-
oratory studies showed thrombocytopenia with platelets at
56,000 k/𝜇L. Serum transaminases elevated to the ∼220 IU/L,
and LDH was in the range of 500s IU/L. He was hospitalized
and received IV fluids and antibiotics. Nevertheless, his
symptoms were further worsening. CBC evaluation showed
leukopeniawithWBCat 1.5 k/𝜇L and thrombocytopeniawith
platelets at 36,000 k/𝜇L. In addition, peripheral blood smear
showed atypical lymphoid cells. CT study demonstrated
hepatosplenomegaly and lymphadenopathy. The patient was
transferred to our hospital for further evaluation approxi-
mately 6 weeks after initial symptoms.
At the time of transfer, the patient demonstrated pro-
found pancytopenia with white blood cell count at 0.6 k/𝜇L,
hemoglobin at 9 g/dL, and platelets at 14 k/𝜇L. Patient also
showed renal insufficiency. His creatinine was elevated to
3.2mg/dL. Additional laboratory studies revealed hyperfer-
ritinemia (∼48000𝜇g/L), hypofibrinogenemia (63mg/dL),
markedly elevated soluble IL-2 receptor (∼57000 pg/mL),
high LDH (2154 IU/L), and mildly increased serum triglyc-
eride. Both EBV-VCA IgM and IgG were positive. PCR study
of EBV titer was marked elevated, >7 million copies/mL.
Peripheral blood smear showed atypical lymphoid cells
with large size, mature chromatin, distinct nucleolus, and
basophilic cytoplasm. Molecular genetic testing for familial
HLH including SH2D1A, BIRC4, and STXBP2 gene was all
normal. The clinical impression was EBV associated sec-
ondary hemophagocytic lymphohistiocytosis. A bone mar-
row evaluation was performed to further characterize the
disease.
2.2. Pathological, Immunophenotypic, Molecular, and Cytoge-
netics Findings. Bone marrow evaluation showed hypocellu-
lar bonemarrowwith decreased trilineage hematopoiesis and
diffuse lymphohistiocytic infiltrates (Figure 1(a)). Increased
histiocytes were seen by H&E and immunohistochemical
stain of CD68 (Figure 1(b)). Histiocytes with evident phago-
cytosis were present in both biopsy (Figure 1(a) and inset)
and bone marrow aspirate (Figure 1(c)). In addition, there
was a very prominent atypical lymphoid cell infiltration
composed of lymphoid cells with medium to large size,
irregular nuclear contour, and visible nucleolus (Figure 1(a)).
Concurrent immunophenotyping by flow cytometric analysis
of marrow aspirate also revealed a prominent atypical T
cell population which was positive for CD2, CD3, and
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Figure 2: Immunophenotypic features of atypical lymphoid infiltrates. (a)–(h) Flow cytometry analysis of bone marrow showed most of
lymphoid infiltrates were CD3+ (a and e), CD2+ (f), CD8+ (b) positive T cells with few CD4+ (b) T cells, and rare CD20+ (a) B cells. These
T cells have bright HLA-DR (c) and CD38 (d) expression. Loss of CD5 (g) and CD7 (h) in T cells was evident. (i)–(n) Immunohistochemical
stains of bone marrow showed a prominent CD3+ (i) and CD8+ (j) T cell infiltration.These T cells are positive for cytotoxic markers perforin
(k), granzyme B (l), and TIA-1 (m) and negative for CD56 (n). (o) In situ hybridization of EBER showed diffuse EBER positive cells in the
bone marrow biopsy. (p) Double immunohistochemical stains of CD3 (red) and EBV-LMP (brown) demonstrated colocalization of EBV and
CD3.
CD8, with uniformly bright CD38 and HLA-DR expression
(Figures 2(a)–2(f)). Loss of CD5 and CD7 antigen expression
in these T cells was easily appreciated (Figures 2(g)-2(h)).
Immunohistochemical work-up on bone marrow biopsy
confirmed that these atypical lymphoid cells are predominant
CD3+/CD8+ T cells (Figures 2(i) and 2(j)) with loss of
CD5 and CD7 antigen expression. In addition, these atypical
lymphoid cells were positive for cytotoxic markers including
perforin, granzyme B, and TIA-1 and negative for CD56
(Figures 2(k)–2(n)). These atypical lymphoid cells were also
positive for EBV as demonstrated by positive EBV LMP
immunohistochemical stain (not shown) and by in situ
hybridization of EBER (Figure 2(o)). Double stain of CD3
and EBV LMP demonstrated colocalization of EBV and CD3
(Figure 2(p)).
In order to further characterize this atypical T cell infil-
tration, PCR of T cell receptor gamma chain gene rearrange-
ment was performed on DNA extracted from bone marrow
aspirate. Two clonal TCR-gamma gene PCR products of ∼
62 and ∼185 bp were identified with V𝛾 1-8,9/J𝛾1/2 primer
set (Figure 3(a)) and one clonal TCR-gamma PCR product
of ∼244 bp was identified with Alt. V𝛾/J𝛾1/2 primer sets
(Figure 3(b)). Therefore, T cell gene rearrangement study
showed a clonal TCR-gamma gene PCR product.

















Figure 3: Molecular and cytogenetics findings in the bone marrow. (a) and (b) Assessment of TCR gamma receptor gene rearrangement by
PCR on formalin-fixed, paraffin-embedded tissue sections from bone marrow clot demonstrated biclonal PCR product using V𝛾 1-8,9/J𝛾1/2
primer set (a) and monoclonal PCR product using Alt. V𝛾/J𝛾1/2 primer sets (b). (c) G-band karyotypic study on bone marrow aspirate
demonstrated an abnormal karyotype in all 20 dividing cells examined: 49,XY,+5,+11,+20/[20].
Cytogenetics study on bone marrow aspirate showed an
abnormal karyotype on all metaphases examined: 49,XY,+5,
+11,+20/[20] (Figure 3(c)).
2.3. Treatment and Posttreatment Clinical Findings. Since
patient met the proposed diagnostic criteria for HLH, he
was started on etoposide, dexamethasone, and Rituxan in
addition to supportive care. Cyclosporin administration was
initially held due to renal insufficiency.Thepatient responded
to the therapy very well. He was discharged to an outside
hospital one week after start of therapy. By the end of 6-week
therapy, he was reported to have normal WBC count, mild
anemia, mild thrombocytopenia, normal ferritin, fibrinogen,
and sIL-2R values. The EBV titer by PCR fell to undetectable
level. Posttherapy bone marrow evaluation demonstrated
hypocellular bone with trilineage hypoplasia. Neither abnor-
mal lymphoid infiltrates nor overt hemophagocytic activities
were identified. Cytogenetic study on the post treatment
marrow showed a normal karyotype [46, XY].
The patient was gradually taken off chemotherapy and
was followed up clinically. Currently, the patient has been
off treatment for three years. He has normal CB except a
persistent borderline thrombocytopenia (platelet count is in
low 100s).There is no clinical concern of HLH or lymphoma-
tous process.
3. Discussion
Primary infection with the EBV in immunocompetent indi-
viduals is characterized by the infection of B lymphocytes
by virus via CD21 antigens on the B cells. Usually it is
asymptomatic. Some of infected patients develop infectious
mononucleosis which is a self-limited disease character-
ized as strong antibody reaction associated with polyclonal
B cell proliferation as well as a robust cytotoxic T cell
response which is often monoclonal or oligoclonal [5].
Uncommonly, acute EBV infection leads to the develop-
ment of hemophagocytic lymphohistiocytosis (HLH), with
unregulated activation of histiocytes and often a clonal
cytotoxic lymphocyte expansion. Clinical and morphology
evaluations demonstrate high fever, hepatosplenomegaly,
lymphadenopathy pancytopenia, hemophagocytosis, hyper-
cytokinemia, and multiorgan system failure. Although EBV-
HLH is associated with substantial morbidity and mortality,
early recognition and prompt immunochemotherapy, such as
HLH 2004 protocol, result in successful treatment of EBV-
induced HLH. Very rarely, EBV infection results in EBV
positive T cell lymphoproliferative disorder of childhoodwith
overt monoclonal T cell proliferation and similar symptoms
as those of EBV-HLH. Most of patients with this disease
have a fulminant clinical course and extremely highmortality
despite aggressive management.
The clinical course and laboratory findings of current
case are compatible with EBV associated HLH. For diagnosis
of HLH, at least 5 out of 8 findings are required [6]. These
findings include (1) persistent fever; (2) splenomegaly; (3)
cytopenias in 2 or more cell lines; (4) hypertriglyceridemia
(triglyceride level ≥265mg/dL) or hypofibrinogenemia (fib-
rinogen level ≤150mg/dL); (5) hemophagocytosis in the
bone marrow, spleen, or lymph nodes; (6) hyperferritinemia
(ferritin level ≥500 ng/mL); (7) impaired NK cell function;
and (8) elevated soluble IL2 receptor. In our case, seven
out of eight findings are identified except for impaired NK
cell function which was not performed due to low WBC
count in the peripheral blood. Given patient’s high EBV titer
and negative molecular study result for primary HLH, it is
compatible with EBV associated secondary HLH.
In addition to these findings consistent with EBV asso-
ciated HLH, evaluation of marrow demonstrated a rather
abundant abnormal CD3+/CD8+ T cell population which
was clonal by TCR gene rearrangement testing. This popu-
lation was composed of EBV positive and cytotoxic CD8+
T cells with evident aberrant loss of CD5 and CD7 antigen
expression.More interestingly, cytogenetic studies of marrow
demonstrated a hyperploid karyotype in all cells examined,
49,XY,+5,+11,+20. These findings are highly suspicious for a
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neoplastic process, particularly systemic EBV-positive T cell
lymphoproliferative disorder of childhood as defined in the
current WHO classification [3].
Systemic EBV-positive T cell lymphoproliferative disor-
der of childhood is a rare clonal T cell neoplasm development
shortly after primary acute EBV infection in previously
healthy children and young adults. Sometimes this entity
can arise in a setting of severe chronic active EBV infection.
Most of caseswere reported in immunocompetentAsians and
Native Americans with a very aggressive clinical course and
very high mortality. The most classical immunophenotype
of this entity is CD3+/CD2+/CD8+ T cells with expression
of selective cytotoxic markers including positive for TIA-
1 and negative for CD56. Loss of CD5 and CD7 antigen
expression in neoplastic T cells is very common. Cases
arising in the setting of severe chronic active EBV infection
are usually CD4+. Rare cases show neoplastic CD4+/CD8+
double positive T cells. Most of neoplastic cells have clonally
rearranged TCR gene and are positive for EBER/EBV-LMP
[3].
Although the morphology and immunohistochemical
cytogenetics/molecular findings in the bone marrow made
us concerned with the diagnosis of EBV-positive T cell
lymphoproliferative disease of childhood, our case presented
with a few unusual characteristics when compared to the
more typical case of EBV-positive T cell lymphoproliferative
disorder of childhood. First of all, typical EBV-positive T cell
lymphoproliferative disorder of childhood is usually found
in children or adolescents of Asian or Native American
origin [3]. It is hypothesized that a genetically determined
susceptibility leads to an abnormal response to primary EBV
infection. By contrast, our patient is a white male without
known immunodeficiency. Secondly, a relatively common
finding in typical EBV-positive T cell lymphoproliferative dis-
ease of childhood is the absence of serologic response to EBV.
EBV anti-VCA IgM was negative in the majority of reported
typical cases whereas EBV anti-VCA IgG is either absent or
only moderately elevated [7]. Sometimes, the negative EBV
serology result may be clinically misleading since it does
not indicate an ongoing EBV infection, which may lead to
a wrong diagnosis path. It has been speculated that the lack
of humoral response to EBV results in virus proliferation in
T cells and subsequently development of clonal expansion of
EBV positive T cells. In contrast, our patient demonstrated a
relatively robust antibody response to EBVwith both positive
EBV anti-VCA IgG and IgM (titer up to 1 : 1280). Ultimately,
systemic EBV-positive T cell lymphoproliferative disorder
of childhood has a very aggressive clinical course with
extremely high mortality which is thought to be related with
uncontrolled HLH. Most of cases have a fulminant course
resulting in death in days tomonth. Only extremely rare cases
showed clinical remission after aggressive chemotherapy.Our
patient had a very good response to HLH 2004 protocol
treatment. Liver function, hematology index, and viral titers
all recovered following treatment. Bonemarrow examination
∼2 months after treatment showed no evidence of clonal
T cell infiltration and normal cytogenetics. Overall these
findings are more compatible with self-limited clonal T cell
proliferation associated with EBV associated HLH.
Aberrant antigen expression in T cells and monoclonal
and oligoclonal T cell expansion in infectious mononucleosis
and EBV associated HLH has been reported previously.
Weisberger et al. [8] demonstrated that acute infectious
mononucleosis is featured by expansion of activated CD8+
cytotoxic T cells with frequent downregulation of CD7 anti-
gen. Bright CD38 and HLA-DR antigen expression in T cells
are noted.Not uncommonly,molecular studies demonstrated
clonal T cell population. Weisberger et al. [8] had proposed
that the bright expression of activation marker of HLA-DR
served as a clue of reactive nature as most of peripheral T
cell neoplasms often have absent to heterogenous expression
of HLA-DR. On the other hand, Toga et al. [9] reported
expanded CD8+ cytotoxic T cells in peripheral blood of six
EBV associated HLH pediatric patients in Japan. Different
from T cells in infectious mononucleosis, these T cells
demonstrated more evident downregulation of CD5 antigen
in addition to loss of CD7 and bright HLA-DR expression
by immunophenotyping. Flow cytometry analysis of TCR
V𝛽 and PCR analysis of TCR beta gene rearrangement
analysis demonstrated T cell clonality in the majority of
patients. Moreover, immunohistochemical studies revealed
that these CD8+ T cells were cellular target of EBV infection
as compared to the B cells which were target of EBV
infection in infectious mononucleosis. Toga proposed that
clonal expansion of CD8+ T cells with CD5 downregulation
as characteristic immunophenotypic features of EBV asso-
ciated HLH as a tool to distinguish patients with infectious
mononucleosis since no such population was identified in
patients with infectious mononucleosis.
Cytogenetics abnormalities have been reported sporad-
ically in EBV associated HLH [10–12]. Imashuku et al.
[11] showed that the EBV associated HLH with abnormal
karyotype is comprised of ∼20% case in a retrospective
cohort of 32 EBV associated HLH cases and was invari-
ably fatal with a 3-year survival of 14%. The majority of
cytogenetically abnormal clone demonstrated hyperdiploid.
However, no recurrent clonal chromosomal abnormality has
been documented in HLH cases with cytogenetics abnor-
malities in their series [11]. A separate study led by Chen
et al. [12] showed 3 cases of EBV-HLH with cytogenetics
abnormality at a single medical center. There is a recurrent
karyotypic abnormality of add(9)(p24) in two of them. Our
patient demonstrated a nonrandomhyperploid karyotype 49,
XY,+5,+11,+20 in all 20 metaphases examined. Usually, clonal
karyotypic abnormality in this clinical setting is an indication
of neoplastic process. However, our patient recovered rather
promptly after typical courses of immunochemotherapy for
HLH. Posttreatment study demonstrates normal karyotype
and the long term follow-up (3-year) showed no evidence of
reoccurrence of disease.
In summary, we report a rare case of EBV-HLHassociated
with evident clonal CD8+T cell expansion.The abundance of
T cell infiltration in the bone marrow, aberrant immunophe-
notypic features, clonality by TCR gamma gene rearrange-
ment, and abnormality by karyocytic cytogenetics study are
highly suspicious for EBV-positive T cell lymphoproliferative
disorder of childhood. However, the clinical course and
responsiveness to the immune chemotherapy are more in
6 Case Reports in Pathology
line with a reactive process. This case further highlights the
diagnostic difficulties to distinguish EBV driven reactive ver-
sus malignant process. Comprehensive evaluation including
morphological, immunophenotypic, molecular, and kary-
otypical studies is important. Clinical correlation, prompt
treatment, and posttreatment follow-up are essential.
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